Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 9/20 | 0.52 |
| ▸ | MAOA | P21397 | 1/20 | 0.50 |
| ▸ | NAAA | Q02083 | 3/20 | 0.48 |
| ▸ | MIF | P14174 | 1/20 | 0.48 |
| ▸ | MAOB | P27338 | 1/20 | 0.48 |
| ▸ | GSK3A | P49840 | 1/20 | 0.47 |
| ▸ | GSK3B | P49841 | 1/20 | 0.47 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6577425 | 1.00 | MAPT (0.53) | MAPTRXFP1SIGMAR1MAOANAAA | |
| SCHEMBL6577459 | 1.00 | MAPT (0.53) | MAPTRXFP1SIGMAR1MAOANAAA | |
| SCHEMBL6577351 | 1.00 | MAPT (0.53) | MAPTRXFP1SIGMAR1MAOANAAA | |
| SCHEMBL11834546 | 1.00 | MAPT (0.53) | MAPTRXFP1SIGMAR1MAOANAAA | |
| SCHEMBL4957180 | 1.00 | MAPT (0.53) | MAPTRXFP1SIGMAR1MAOANAAA | |
| SCHEMBL6579084 | 1.00 | MAPT (0.53) | MAPTRXFP1SIGMAR1MAOANAAA | |
| SCHEMBL6577458 | 1.00 | MAPT (0.53) | MAPTRXFP1SIGMAR1MAOANAAA | |
| SCHEMBL1772170 | 1.00 | MAPT (0.53) | MAPTRXFP1SIGMAR1MAOANAAA | |
| SCHEMBL96647 | 0.98 | MAOA (0.52) | MAPTRXFP1SIGMAR1MAOANAAA | |
| SCHEMBL97266 | 0.91 | HDAC3 (0.50) | MAPTRXFP1SIGMAR1MAOAMIF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1105 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116063666-B | Multifunctional polyester material and preparation method and application thereof | 四川大学 | 2024-04-19 | — | — | CN | claimed |
| CN-116063666-A | Multifunctional polyester material and preparation method and application thereof | 四川大学 | 2023-05-05 | — | — | CN | claimed |
| CN-113444005-A | Method for synthesizing novel glutaric acid compound from diaryl substituted non-activated olefin | 四川大学 | 2021-09-28 | — | — | CN | claimed |
| WO-2009026422-A2 | TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | ABBOTT LABORATORIES (US) | 2009-02-26 | — | — | WO | claimed |
| US-6875740-B1 | Combination of a cyclic hexapeptide with antifungal drugs for treatment of fungal pathogens | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2005-04-05 | — | — | US | claimed |
| US-5541303-A | 3,4'-dideoxymycaminosltylonolide derivative and process for producing the same | ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYUKAI (JP) | 1996-07-30 | — | — | US | claimed |
| CN-116063666-B | Multifunctional polyester material and preparation method and application thereof | 四川大学 | 2024-04-19 | — | — | CN | disclosed |
| US-20240084308-A1 | FIBROTIC TREATMENT | MONASH UNIVERSITY (AU) | 2024-03-14 | — | — | US | disclosed |
| US-20240034845-A1 | POLYMER PARTICLES | QUEENSLAND UNIVERSITY OF TECHNOLOGY (AU) | 2024-02-01 | — | — | US | disclosed |
| EP-3384549-B1 | SODIUM-ION ELECTROLYTE COMPOSITION | UNIV DEAKIN (AU) | 2024-01-17 | — | — | EP | disclosed |
| US-11834663-B2 | Fibrotic treatment | MONASH UNIVERSITY (AU) | 2023-12-05 | — | — | US | disclosed |
| US-20230348674-A1 | HYDROGELS | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2023-11-02 | — | — | US | disclosed |
| WO-2023190111-A1 | RAFT POLYMERIZATION REACTION SOLUTION AND RAFT POLYMERIZATION REACTION SOLUTION PRODUCTION METHOD | テクノＵＭＧ株式会社 | 2023-10-05 | — | — | WO | disclosed |
| EP-0030630-A2 | 7-Acylamino-3-vinylcephalosporanic acid derivatives, processes for their preparation, pharmaceutical compositions containing them; their starting compounds and their preparation | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1981-06-24 | — | — | EP | disclosed |
| EP-0029557-A2 | 7-Acylamino-3-substituted cephalosporanic acid derivatives, processes for their preparation and pharmaceutical compositions containing them | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1981-06-03 | — | — | EP | disclosed |
| EP-0010667-A1 | Cepham compounds, pharmaceutical compositions containing them and processes for the preparation thereof and of known cephem compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1980-05-14 | — | — | EP | disclosed |
| US-4088537-A | BIOTRANSFORMATION | THE UPJOHN COMPANY (US) | 1978-05-09 | — | — | US | disclosed |
| US-4041055-A | SULFENYLATION, MICHAEL ADDITION, REACTION WITH THIOPHILE, HYDROLYSIS | THE UPJOHN COMPANY (US) | 1977-08-09 | — | — | US | disclosed |
| US-3975532-A | ANALGESIC | ICI UNITED STATES INC. (US) | 1976-08-17 | — | — | US | disclosed |
| US-3953596-A | 8-Oxa-3-azabicyclo(3.2.1)octane analgesic compositions and method of alleviating pain in animals | ICI UNITED STATES INC. (US) | 1976-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11834663-B2 | Fibrotic treatment | MMP1, ENPEP, RNPEP | MAPT 3950/4885RXFP1 103/4885SIGMAR1 4840/4885 |
| US-20230348674-A1 | HYDROGELS | PHYKPL, TST, PHOSPHO1 | MAPT 3246/4885RXFP1 3700/4885SIGMAR1 1231/4885 |
| US-20240084308-A1 | FIBROTIC TREATMENT | MMP1, ENPEP, RNPEP | MAPT 3950/4885RXFP1 103/4885SIGMAR1 4840/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.